Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
36 Results for "
Glycoprotein VI
" in MedChemExpress (MCE) Product Catalog:
Products (36)
36 Results for "Glycoprotein VI" in MCE Product Catalog:
2
Target:
Research Areas:
Lanraplenib (GS-9876) is a highly selective and orally active SYK inhibitor (IC50=9.5 nM) in development for the treatment of inflammatory diseases. Lanraplenib (GS-9876) inhibits SYK activity in platelets via the glycoprotein VI (GPVI) receptor without prolonging bleeding time (BT) in monkeys or humans .
2
2 Cited Publications
Cat. No.: HY-P99644
CAS No.: 2101829-58-5
Target:
Research Areas:
2
2 Cited Publications
Synonyms: GS-9876 succinate
Target:
Research Areas:
Lanraplenib succinate (GS-9876 succinate) is a highly selective and orally active SYK inhibitor (IC50=9.5 nM) in development for the treatment of inflammatory diseases. Lanraplenib succinate (GS-9876 succinate) inhibits SYK activity in platelets via the glycoprotein VI (GPVI) receptor without prolonging bleeding time (BT) in monkeys or humans .
2
2 Cited Publications
Synonyms: GPVI antagonist 1
Target:
Research Areas:
(S)-S007-1558 (compound 5) is a glycoprotein VI (GPVI) platelet receptor antagonist. (S)-S007-1558 inhibits collagen-induced platelet aggregation with an IC50 of 25.3 μM .
1
Target:
Research Areas:
Codrituzumab (GC33) is a humanized monoclonal antibody targeting human GPC3 (glypican-3), with high affinity (Kd of 0.673 nM). GPC3 is an oncofetal protein expressed on the cell surface of hepatocellular carcinoma (HCC). Codrituzumab induces antibody-dependent cellular cytotoxicity (ADCC) and inhibits tumor growth .
1
1
1 Cited Publications
Cat. No.: HY-P77952
Purity: ≥ 95%, as determined by reducing SDS-PAGE or Bis-Tris PAGE.
Synonyms: GP6; Glycoprotein VI (Platelet); Glycoprotein VI Platelet; Platelet Collagen Receptor; GPVI; BDPLT11; Platelet Glycoprotein VI; GPIV; Glycoprotein 6
Species:
Human
Source:
HEK293
Cat. No.: HY-W1124925
CAS No.: 3066439-94-6
Research Areas:
Cat. No.: HY-P10888A
Target:
Research Areas:
Cat. No.: HY-P990841
Target:
Research Areas:
Cat. No.: HY-P10888
CAS No.: 3066113-41-2
Target:
Research Areas:
Synonyms: Losartan Carboxaldehyde; DuP 167
Research Areas:
EXP3179 (Losartan Carboxaldehyde) is a metabolite of Losartan (HY-17512). EXP3179 binds to AT1R with an affinity of 20 nM and blocks ANGII-induced AT1R signaling, inhibiting ERK1/2 activation. EXP3179 reduces NADPH oxidase activity. EXP3179 inhibits Phenylephrine (HY-B0769)-induced aortic contraction through an endothelium-dependent, NO-dependent mechanism. EXP3179 dose-dependently inhibits type I collagen-induced platelet aggregation and activation through GPVI binding, reducing platelet adhesion to the injured site. EXP3179 lowers blood pressure in normotensive and spontaneously hypertensive rats and mice. EXP3179 can be used for research on type 2 diabetes, hypertensive heart disease, hypertension, thrombosis, and coronary artery disease .
Cat. No.: HY-P990840
Target:
Research Areas:
Cat. No.: HY-125053A
Purity: 99.58%
Target:
Research Areas:
Cat. No.: HY-P990842
Target:
Research Areas:
Cat. No.: HY-P991448
Target:
Research Areas:
Cat. No.: HY-115911
CAS No.: 880399-00-8
Target:
Research Areas:
GPVI antagonist 2 (Compound 1) is a potential antagonist of Glycoprotein VI (GPVI). IC50 values of GPVI antagonist 2 are, respectively, 0.35 μM for collagen, 0.80 μM for CRP, 195.2 μM for convulxin and 81.38 μM for thrombin. Glycoprotein VI (GPVI) is a platelet major collagen receptor and a target for potent and safe antithrombotic research. GPVI antagonist 2 is a promising antiplatelet agent .
Cat. No.: HY-115912
CAS No.: 901654-94-2
Target:
Research Areas:
GPVI antagonist 3 (Compound 2) is a potential antagonist of Glycoprotein VI (GPVI). IC50 values of GPVI antagonist 3 are, respectively, 1.01 μM for collagen, 1.92 μM for CRP, 7.24 μM for convulxin and 51.74 μM for thrombin. Glycoprotein VI (GPVI) is a platelet major collagen receptor and a target for potent and safe antithrombotic research. GPVI antagonist 3 is a promising antiplatelet agent .
Cat. No.: HY-P10949
CAS No.: 1159846-95-3
Target:
Research Areas:
Cat. No.: HY-109091A
CAS No.: 1800046-97-2
Synonyms: GS-9876 monosuccinate
Target:
Research Areas:
Lanraplenib monosuccinate (GS-9876 monosuccinate) is a highly selective and orally active SYK inhibitor (IC50=9.5 nM) in development for the treatment of inflammatory diseases. Lanraplenib monosuccinate (GS-9876 monosuccinate) inhibits SYK activity in platelets via the glycoprotein VI (GPVI) receptor without prolonging bleeding time (BT) in monkeys or humans .
- 1
- 2
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
